Company
Epion Therapeutics
Developing the future standard of care for keratoconus and corneal ectasia
- Status
- Operatingas of 2026-09-18
Claim, correct or request removal
Record updated 18 September 2026
About
Epion Therapeutics is developing a minimally-invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally. Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.
Funding snapshot
- Total raised
- $32MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series A, $32M2022-09-30
Funding rounds
- Series A
- $32M2022-09-30, Company stated
Products
- Hardware
- EpiSmart
Loading relationship preview